The advent of imatinib, the first BCR–ABL1 tyrosine kinase inhibitor (TKI), has dramatically improved the prognosis of CML [1,2,3] and has become standard therapy for CML since 2001 [4,5]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.